Investigational drug · Phase 2
LEO 138559
Also called: LEO 138559 is also called "temtokibart"
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Atopic Dermatitis.
Phase 2Last checked: Nov 20, 2026Latest source record: Feb 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
5
Any phase or sponsor naming "LEO 138559"
First trial start
2023
Sep 20, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LEO 138559", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atopic Dermatitis
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "LEO 138559" as an intervention, largest first.
- A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic DermatitisPivotal-lookingCompleted
LEO PharmaIndustry
NCT05923099 · 262 participants · Start Sep 20, 2023 · Primary completion Dec 11, 2024
Drug: LEO 138559; Placebo · For: Atopic Dermatitis
Sites: Fountain Valley, California; Los Angeles, California; San Francisco, California · 73 sites in all
LEO PharmaIndustry
NCT04922021 · 58 participants · Start Jul 14, 2021 · Primary completion Jun 2, 2022
Drug: LEO 138559; LEO 138559 placebo · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Fountain Valley, California; Los Angeles, California · 17 sites in all
- Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic DermatitisCompleted
LEO PharmaIndustry
NCT03514511 · 47 participants · Start May 7, 2018 · Primary completion Mar 2, 2021
Drug: LEO 138559; LEO 138559 placebo · For: Atopic Dermatitis
Sites: Leeds, United Kingdom; Liverpool, United Kingdom; Manchester, United Kingdom
LEO PharmaIndustry
NCT05099133 · 24 participants · Start Nov 3, 2021 · Primary completion Jun 28, 2022
Drug: LEO 138559; LEO 138559 Placebo · For: Atopic Dermatitis
Sites: Los Angeles, California
LEO PharmaIndustry
NCT05470114 · 13 participants · Start May 19, 2022 · Primary completion Jun 7, 2023
Drug: LEO 138559; Dupixent® · For: Atopic Dermatitis
Sites: Vienna, Austria
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Atopic Dermatitis
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.